WO1998014200A1 - The regulation of appetite, body weight and athletic function with materials derived from citrus varieties - Google Patents
The regulation of appetite, body weight and athletic function with materials derived from citrus varieties Download PDFInfo
- Publication number
- WO1998014200A1 WO1998014200A1 PCT/US1996/016213 US9616213W WO9814200A1 WO 1998014200 A1 WO1998014200 A1 WO 1998014200A1 US 9616213 W US9616213 W US 9616213W WO 9814200 A1 WO9814200 A1 WO 9814200A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- citrus
- synephrine
- amount
- group
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/32—Tin compounds
Definitions
- the present invention relates to the use of materials derived from Citrus plants in
- thermogenic responsiveness during chronic ephedrine treatment in man is a parameter that influences the rate of chronic ephedrine treatment in man. Am. J. Clin. Nutr.,
- Caffeine a double-blind, placebo-controlled study of its thermogenic, metabolic and
- thermogenic drugs Am J Clin Nutr , 55, 246S - 248S
- thermogenesis potential use in the treatment of obesity Am J Clin Nutr , 45, 564 - 569
- thermogenesis induced by ephedrine and caffeine in brown adipose tissue Int J Obes , 15,
- composition composition, blood chemistry, vital signs, and self-reported energy levels & appetite control.
- Some such substances act by mimicking the effects of endogenous neurotransmitters, and are capable of directly replacing these
- receptors concerned are normally responsive to the endogenous hormones adrenaline (epinephrine) and noradrenaline (norepinephrine), which are normally responsive to the endogenous hormones adrenaline (epinephrine) and noradrenaline (norepinephrine), which are normally responsive to the endogenous hormones adrenaline (epinephrine) and noradrenaline (norepinephrine), which are normally responsive to the endogenous hormones adrenaline (epinephrine) and noradrenaline (norepinephrine), which are normally responsive to the endogenous hormones adrenaline (epinephrine) and noradrenaline (norepinephrine), which are normally responsive to the endogenous hormones adrenaline (epinephrine) and noradrenaline (norepinephrine), which are normally responsive to the endogenous hormones adrenaline (epinephrine) and noradrenaline (nor
- Ephedrine is a typical example of an indirect-acting sympathicomimetic agent.
- adrenergic may also be used, and is synonymous with the
- sympathicomimetic Such substances may also be referred to as agonists, where the
- name agonist is qualified by a descriptor of the receptor stimulated, for example, a
- beta-agonist While the formal distinction between direct-acting and indirect-acting
- amphetamines act mainly directly, but also have some indirect
- amphetamines which are direct agents and readily cross the blood-brain
- barrier mainly cause central nervous system stimulation, while ephedrine, and particularly
- pseudoephedrine are indirect agents which do not cross the blood-brain barrier so readily, and
- Another class of substances of value in assisting weight loss modulates other
- neurotransmitters namely those involved in serotoninergic systems, and particularly
- 5-hydroxytryptamine ( otherwise known as serotonin) itself.
- These substances act by preventing the re-uptake of serotonin into storage granules in neurones.
- Levels of 5-HT in the synaptic gap are typical, act by preventing the re-uptake of serotonin into storage granules in neurones.
- tachyphylaxis 2 sensitivity is termed tachyphylaxis.
- thermogenesis 5 shown that ephedrine acts mainly by stimulating thermogenesis. That is, it increases the metabolic rate and stimulates lipolysis (fat breakdown).
- composition of the diet may even result in a gain of body protein (anabolic effect).
- methylxanthines such as caffeine
- ephedrine may be an example of a trace substance that
- ephedrine may therefore be considered an ideal
- ephedrine' s main mode of action appears to be peripheral and, in part, causative since it offsets
- thermogenic action which results from ephedrine' s effects on metabolic rate
- lipolysis persists throughout its use period, and may intensify as use continues.
- Ephedrine ' s classical adrenergic actions, which are undesirable in a weight loss
- narcolepsy to combat hypotensive states (especially those associated with spinal anesthesia), in the management of enuresis, as adjunctive therapy for myasthenia gravis, as a mydriatic, as
- ketotic hypoglycaemia Court et al.
- ephedrine on the internal sphincter of the bladder and urethra in relation to its use in treating
- pseudoephedrine essentially shares these properties, but is mainly used for relief of rhinitis in
- pseudoephedrine and ephedrine have similar pharmacological profiles, but that
- pseudoephedrine is less potent.
- Naturally occurring ephedrine is the lR,2S(-)-erythro form, which is the most active
- Pseudoephedrine is the threo form.
- beta-adrenoceptors The perceived effects on different organs and tissues depend on the
- beta-receptors results in stimulation of adenylate
- the beta-agonist binds to the beta-receptor.
- the receptor-agonist complex has high affinity for a stimulatory guanine
- Gs protein nucleotide regulatory protein
- GDP guanine diphosphate
- GTP guanine triphosphate
- the cAMP activates a cAMP-dependent protein kinase, which can then
- Gi guanine nucleotide regulatory protein
- the Gi protein by inhibiting the catalytic activity of the adenylate cyclase, leads to a reduction
- the Gi protein may act through other
- beta-receptors can also be further subdivided based upon their mechanism of action.
- the known subdivision of beta-receptors into beta-1, beta-2, and beta-3 types is of particular interest for this invention since the beta-3 -receptor is strongly
- beta-receptors causes vasodilation of vessels in the heart and skeletal muscle while
- thermogenesis In the case of lipolysis, activation of alpha-2-receptors inhibits the process
- beta-receptors (believed to be the beta-3 -subtype) stimulates lipolysis
- thermogenic response The overall response of the adipose tissue thus depends on the relative proportions
- alpha-2 and beta-3 receptors A high ratio of alpha-2 to beta-3 receptors would produce a high ratio of alpha-2 and beta-3 receptors.
- thermogenic response comparatively lower thermogenic response than a low ratio.
- thermogenic responses may explain why some studies of thermogenic responses to
- ephedrine have found two populations: responders and relative non-responders.
- ephedrine has little or no direct agonist activity but
- noradrenaline released by ephedrine activate the beta-3 -adrenoceptors.
- the adrenaline released is a preferential agonist for the beta-2-adrenoceptors which stimulate protein synthesis and thus can counteract loss of lean body mass during
- thermogenesis adrenoceptor types that mediate thermogenesis, lipolysis and protein retention.
- Arner (1993) approaches the mechanism of ephedrine action from the lipolysis aspect.
- prostaglandins of the E-type are also potent antilipolytic agents.
- the potentiation of the E-type is also potentiation of the E-type.
- inhibit prostaglandin synthysis may not be restricted to the synaptic gap, but may also extend
- thermogenic and lipolytic effects are the main properties that
- the acute action is to increase energy
- Ephedrine has some drawbacks, however. It is primarily
- Ephedra herb (Ephedraceae), which contains ephedrine together with related
- the present invention relates to the discovery that certain plants contain adrenergic
- methyltyramine that are useful to assist in weight loss, adding muscle mass, and/or increasing
- the present invention relates to the discovery that
- the invention relates to the discovery that these useful levels only
- the invention relates to a composition
- the invention relates to the use of the composition to stimulate beta-
- the invention relates to the use of the composition to control appetite by suppressing hunger.
- composition of the invention has utility in regulating or treating weight problems as well as increasing vitality, energizing, and in the long term increasing
- the amounts of the adrenergic amines of this invention needed to be effective can be as low as one mg ingested three times daily, and the low dosage effective range is from one to five mg ingested up to 3 or 4 times daily. Still further, the preferred use
- total daily dose of about 100 to 120 mg per day.
- the present invention relates to a method for weight loss and a
- An object of the present invention is to provide a composition containing an effective
- Another object of the present invention is to provide a composition containing an
- Yet another object of the present invention is to provide a composition containing an
- Still another object of the invention is a method for promoting weight control, weight
- lean muscle mass which includes cZ xO the step of administering to a subject an effective amount of at least one of the group of five
- Another object of the invention is to obtain the adrenergic amines from the plant
- material of the genus Citrus and more specifically from the leaves, bark, unripe fruit, ripe fruit
- one feature of the invention is that the
- composition can be administered in the form of the plant material in a tablet, capsule or other
- pharmacologically appropriate carrier in the form of a tea, or in the form without plant
- Figure 1 shows the chemical structures of the five alkaloids: synephrine, hordenine,
- Ephedraceae may also act as sympathicomimetic agents with suitable mechanisms of action in
- the agents are generally only
- the agents contained in the plants which are used in accordance with the invention include synephrine, hordenine, octopamine, tyramine and N-methyltyramine, and they may be found in various species of plants, both food plants and otherwise, as detailed by Wheaton and
- Citrus reticulata also known as tangerine or mandarin orange
- aurantium also known as C. florida, C. vulgaris, C. bigaradia, Sour orange, Bitter orange,
- Citrus species have been used, and continue to be used, for a variety of Citrus species.
- Zhi shi The immature (dried) fruit of Citrus aurantium is used for the treatment of
- Zhi Qiao This herb is also the immature fruit of Citrus aurantium, and is used to treat
- Chen pi The herb Chen pi is dried peel of Citrus reticulata. This may also be called Jiu
- the herb also has anti-infective properties (Ou Ming, op. cit.).
- Qing pi This herb is immature Citrus reticulata, or in some cases the peel thereof. It is
- Fo Shou Also known as Fructus Citri Sarcodactyli, the fruit of Citrus medica var.
- sarcodactylus it is used for treatment of digestive disorders, for dysmenorrhea, chest
- Chen pi dried ripe
- the seeds is used to treat lumbago, orchitis and mastitis.
- Wichtl also reports that dried peel of Citrus aurantium, or the dried whole immature fruit, is used in gastrointestinal remedies, tonics, roborants and cholagogues.
- Grieve (1992) describes use of lemon juice for the treatment of rheumatism, and of the oils from
- Font Quer (1982) refers to the
- the active agents synephrine, hordenine, octopamine, tyramine and N-methyltyramine
- tyramine as a diagnostic agent in suspected cases of phaeochromocytoma
- Citrus material used in accordance with the invention may consist of any portion
- leaves of Citrus reticulata are preferred to other parts of this plant, and may show levels of
- synephrine and related alkaloids of 1.1% or more, based on dry matter, while the peel of the
- the Chinese herbs which are most convenient for use are:
- o Zhi shi which is the immature (dried) fruit of Citrus aurantium, but may also
- This herb consist of the peel of the mature fruit, or the peel of either. This herb contains 0.2% - 0.9%
- o Chen pi the dried peel of Citrus reticulata
- This herb contains 0.1% - 0.4% total alkaloids.
- o Qing pi is the dried immature Citrus reticulata, or in some cases the peel thereof. This herb contains 0.1% - 0.4% total alkaloids.
- material from Citrus species is given to humans by the oral route, either concurrently with caloric restriction or in the absence of caloric restriction, for the purpose of controlling body weight.
- the invention works
- thermogenesis predominantly by increasing thermogenesis, that is, by increasing the metabolic rate
- the invention also exhibits a hunger-suppressing effect which may
- said material can be given to humans, either with or without a high protein diet (>1.25 gm
- the Citrus material so used is selected for its content of active agents as defined above
- body weight per serving will be effective in accomplishing the desired goal of weight loss
- tachycardia tachycardia
- nervousness agitation
- tremors and insomnia.
- invention is in the range of 0.16 mg to 1 mg per kilogram of ideal body weight. Thus, an adult
- the active agents are deemed to be any one or more of synephrine,
- Citrus material may be difficult to achieve an intake of Citrus material in a volume sufficient to provide a
- the Citrus material may be consumed as a concentrate or as an
- the material may be enriched in the agents, for example, by extraction of the Citrus material with
- Such a suitable material may include, but is not limited to, maltodextrins,
- the Citrus material may also be any organic compound.
- the Citrus material is preferably dried so
- the Citrus material When prepared as a liquid extract, the Citrus material may be consumed as drops, or
- the Citrus material may be given
- the dried leaves of Citrus reticulata var. Blanco may be filled into tea
- Citrus materials may also be admixed with other ingredients to form the basis of a dietary product, which may either be a nutritional drink or a nutritional bar.
- a nutritional product which may either be a nutritional drink or a nutritional bar.
- One such nutritional bar can provide 15 grams of protein, 26 grams of carbohydrate and 5 grams of fat
- Such products may thus be used as meal replacements by those seeking to lose weight, or by those requiring nutritional support during
- the Citrus material may also be given in combination with other herbs that possess beneficial effects for humans, and particularly in respect to weight loss or improvements in physical performance. In this
- suitable herbs and foods include those herbs and foods that contain methylxanthines such as caffeine, theobromine and theophylline, which by virtue of their
- methylxanthines on alpha-receptors may serve to reduce or eliminate any unwanted cardiovascular effects, such as peripheral vasoconstriction and increase in blood
- Suitable herbs and foods in this respect include, but are not limited to, Paullinia
- the herb so chosen is admixed with the Citrus material in a suitable form to provide a solid or liquid dosage unit.
- Example 2 A portion of the Zhi shi powder used in Example 2 was concentrated by extraction
- Example 5 was filled into capsules as in Example 2 to provide a product with 18 mg alkaloids of the c3 synephrine group per capsule. Subjects DJ and HAF then took 1 capsule of this product 3 times daily for four weeks, providing a daily intake of 54 mg synephrine and related alkaloids. During this time, subject DJ, without deliberate restriction of food intake, showed a decrease
- Example 4 Two batches of nutrition bars were prepared using the Thermobar concept, that is, chocolate-flavored taffy bars weighing 57 grams providing 15 grams protein, 26 grams
- thermogenic effect of the ingested alkaloids indicating a thermogenic effect of the ingested alkaloids.
- Example 5 A group of 9 women, of whom 6 were mildly obese, 1 moderately obese and 2 slightly
- Citrus aurantium (immature whole fruit) extract 125 mg of a dried Paullinia cupana extract, 5
- the Citrus aurantium extract contained 4.14% total
- each subject completed a daily mood, appetite and satiety rating questionnaire.
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES96934144T ES2339908T3 (en) | 1996-09-30 | 1996-09-30 | REGULATION OF BODY WEIGHT WITH MATERIALS DERIVED FROM VARIETIES OF THE CITRUS GENRE. |
CA002248854A CA2248854C (en) | 1996-09-30 | 1996-09-30 | The regulation of appetite, body weight and athletic function with materials derived from citrus varieties |
AT96934144T ATE453385T1 (en) | 1996-09-30 | 1996-09-30 | REGULATION OF BODY WEIGHT THROUGH MATERIALS BASED ON CITRUS VARIATIONS |
PCT/US1996/016213 WO1998014200A1 (en) | 1996-09-30 | 1996-09-30 | The regulation of appetite, body weight and athletic function with materials derived from citrus varieties |
US09/142,197 US6224873B1 (en) | 1996-09-30 | 1996-09-30 | Regulation of appetite, body weight and athletic function with materials derived from citrus varieties |
DE69638106T DE69638106D1 (en) | 1996-09-30 | 1996-09-30 | Regulation of body weight by materials based on citrus variations |
EP96934144A EP0885008B1 (en) | 1996-09-30 | 1996-09-30 | The regulation of body weight with materials derived from citrus varieties |
US09/573,321 US6340481B1 (en) | 1996-09-30 | 2000-05-18 | Regulation of athletic function with materials derived from citrus varieties |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1996/016213 WO1998014200A1 (en) | 1996-09-30 | 1996-09-30 | The regulation of appetite, body weight and athletic function with materials derived from citrus varieties |
Related Child Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/142,197 A-371-Of-International US6224873B1 (en) | 1996-09-30 | 1996-09-30 | Regulation of appetite, body weight and athletic function with materials derived from citrus varieties |
US09/573,321 Division US6340481B1 (en) | 1996-09-30 | 2000-05-18 | Regulation of athletic function with materials derived from citrus varieties |
US09/573,324 Continuation US6340482B1 (en) | 1998-08-31 | 2000-05-18 | Methods for inducing weight loss in a human with materials derived from Citrus varieties |
US09/573,320 Division US6316499B1 (en) | 2000-05-18 | 2000-05-18 | Methods for increasing the muscle mass of a human with materials derived from citrus varieties |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998014200A1 true WO1998014200A1 (en) | 1998-04-09 |
Family
ID=41480338
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/016213 WO1998014200A1 (en) | 1996-09-30 | 1996-09-30 | The regulation of appetite, body weight and athletic function with materials derived from citrus varieties |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0885008B1 (en) |
AT (1) | ATE453385T1 (en) |
CA (1) | CA2248854C (en) |
DE (1) | DE69638106D1 (en) |
ES (1) | ES2339908T3 (en) |
WO (1) | WO1998014200A1 (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1010429A2 (en) * | 1998-12-11 | 2000-06-21 | ROEDER 1956 FARMACEUTICI S.p.A. | Pharmaceutical composition, in particular for dietetical use comprising a derivative of pyruvic acid and unripe bitter orange extract |
WO2001045693A1 (en) * | 1999-12-21 | 2001-06-28 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Use of carboxy compounds such as 2(4-acetoxyphenyl)-2-chloro-n-methyl-ethylammonium chloride as anti-inflammatory agents |
FR2802811A1 (en) * | 1999-12-24 | 2001-06-29 | Silab Sa | Production of agent for combating cellulite and improving skin condition comprises extracting Seville orange petals with mixture of water and propylene glycol |
US6316499B1 (en) * | 2000-05-18 | 2001-11-13 | Zhishin, Llc | Methods for increasing the muscle mass of a human with materials derived from citrus varieties |
US6340481B1 (en) * | 1996-09-30 | 2002-01-22 | Zhishin, Llc | Regulation of athletic function with materials derived from citrus varieties |
US6447818B1 (en) * | 1999-10-20 | 2002-09-10 | Ambros Pharma S.R.L. | Compositions containing compounds with adrenergic activity and vegetable extracts of Crataegus and gingko biloba for the treatment of overweight and obesity |
US6576272B1 (en) * | 1999-03-05 | 2003-06-10 | Twin Laboratories Incorporated | Dietary supplement and method of using same |
WO2003097077A1 (en) * | 2002-05-15 | 2003-11-27 | Zhishin Inc. | Novel dosage forms for materials derived from citrus varieties |
WO2003097078A1 (en) * | 2002-05-15 | 2003-11-27 | Zhishin Inc. | Nutraceutical compositions comprising citrus alkaloids and method |
US9044606B2 (en) | 2010-01-22 | 2015-06-02 | Ethicon Endo-Surgery, Inc. | Methods and devices for activating brown adipose tissue using electrical energy |
WO2016196205A1 (en) | 2015-05-29 | 2016-12-08 | Johnson & Johnson Consumer Inc. | Use of organic citrus extract with high antimicrobial capacity as a preservative system in liquids, emulsions, suspensions, creams and antacids |
WO2016196209A1 (en) | 2015-05-29 | 2016-12-08 | Johnson & Johnson Consumer Inc. | Use of an organic citrus extract with high antimicrobial capacity and xylitol as a preservative system in liquids, emulsions, suspensions, creams and antacids |
US10080884B2 (en) | 2014-12-29 | 2018-09-25 | Ethicon Llc | Methods and devices for activating brown adipose tissue using electrical energy |
US10092738B2 (en) | 2014-12-29 | 2018-10-09 | Ethicon Llc | Methods and devices for inhibiting nerves when activating brown adipose tissue |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4842859A (en) * | 1986-09-08 | 1989-06-27 | Yaguang Liu | Pharmaceutical compositions for reducing hyperlipidemia and platelet-aggregation |
US5002930A (en) * | 1984-08-08 | 1991-03-26 | Survival Technology, Inc. | Protein absorption enhancing agents |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR5164M (en) * | 1966-02-23 | 1967-06-12 | ||
DK339289D0 (en) * | 1989-07-07 | 1989-07-07 | Dak Lab As | PHARMACEUTICAL PREPARATION |
-
1996
- 1996-09-30 AT AT96934144T patent/ATE453385T1/en not_active IP Right Cessation
- 1996-09-30 CA CA002248854A patent/CA2248854C/en not_active Expired - Fee Related
- 1996-09-30 WO PCT/US1996/016213 patent/WO1998014200A1/en active Application Filing
- 1996-09-30 EP EP96934144A patent/EP0885008B1/en not_active Expired - Lifetime
- 1996-09-30 DE DE69638106T patent/DE69638106D1/en not_active Expired - Lifetime
- 1996-09-30 ES ES96934144T patent/ES2339908T3/en not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5002930A (en) * | 1984-08-08 | 1991-03-26 | Survival Technology, Inc. | Protein absorption enhancing agents |
US4842859A (en) * | 1986-09-08 | 1989-06-27 | Yaguang Liu | Pharmaceutical compositions for reducing hyperlipidemia and platelet-aggregation |
Non-Patent Citations (2)
Title |
---|
CHEMICAL ABSTRACTS, Volume 115, Number 10, issued 09 September 1991, ASTRUP A., "An Antiobesity Pharmaceutical Composition Containing Beta-Adrenergic Agonist and a Xanthine", page 6504, Abstract No. 99277y; & WO,A,91 00730. * |
CHEMICAL ABSTRACTS, Volume 121, Number 15 issued 10 October 1994, BLAU et al., "Metabolic Integration in Locus Flight: The Effect of Octopamine on Fructose 2,6-Bisphosphate Content of Flight Muscle In Vivo", Abstract No. 175656n; & J. COMP. PHYSIOL. B., 164(1), pages 11-15, (Eng). * |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6340481B1 (en) * | 1996-09-30 | 2002-01-22 | Zhishin, Llc | Regulation of athletic function with materials derived from citrus varieties |
EP1010429A2 (en) * | 1998-12-11 | 2000-06-21 | ROEDER 1956 FARMACEUTICI S.p.A. | Pharmaceutical composition, in particular for dietetical use comprising a derivative of pyruvic acid and unripe bitter orange extract |
EP1010429A3 (en) * | 1998-12-11 | 2001-11-28 | ROEDER 1956 FARMACEUTICI S.p.A. | Pharmaceutical composition, in particular for dietetical use comprising a derivative of pyruvic acid and unripe bitter orange extract |
US6576272B1 (en) * | 1999-03-05 | 2003-06-10 | Twin Laboratories Incorporated | Dietary supplement and method of using same |
US6447818B1 (en) * | 1999-10-20 | 2002-09-10 | Ambros Pharma S.R.L. | Compositions containing compounds with adrenergic activity and vegetable extracts of Crataegus and gingko biloba for the treatment of overweight and obesity |
US7053120B2 (en) | 1999-12-21 | 2006-05-30 | Gent Universiteit | Use of carboxy compounds such as 2(4-acetoxyphenyl)2-chloro-N-methyl-ethylammonium chloride as anti-inflammatory agents |
WO2001045693A1 (en) * | 1999-12-21 | 2001-06-28 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Use of carboxy compounds such as 2(4-acetoxyphenyl)-2-chloro-n-methyl-ethylammonium chloride as anti-inflammatory agents |
FR2802811A1 (en) * | 1999-12-24 | 2001-06-29 | Silab Sa | Production of agent for combating cellulite and improving skin condition comprises extracting Seville orange petals with mixture of water and propylene glycol |
US6316499B1 (en) * | 2000-05-18 | 2001-11-13 | Zhishin, Llc | Methods for increasing the muscle mass of a human with materials derived from citrus varieties |
WO2003097078A1 (en) * | 2002-05-15 | 2003-11-27 | Zhishin Inc. | Nutraceutical compositions comprising citrus alkaloids and method |
WO2003097077A1 (en) * | 2002-05-15 | 2003-11-27 | Zhishin Inc. | Novel dosage forms for materials derived from citrus varieties |
US9044606B2 (en) | 2010-01-22 | 2015-06-02 | Ethicon Endo-Surgery, Inc. | Methods and devices for activating brown adipose tissue using electrical energy |
US11040196B2 (en) | 2010-01-22 | 2021-06-22 | Cilag Gmbh International | Methods and devices for activating brown adipose tissue using electrical energy |
US10201695B2 (en) | 2010-01-22 | 2019-02-12 | Ethicon Endo-Surgery, Inc. | Methods and devices for activating brown adipose tissue using electrical energy |
US9662486B2 (en) | 2010-01-22 | 2017-05-30 | Ethicon Endo-Surgery, Inc. | Methods and devices for activating brown adipose tissue using electrical energy |
US10207102B2 (en) | 2014-12-29 | 2019-02-19 | Ethicon Llc | Methods and devices for activating brown adipose tissue using electrical energy |
US10092738B2 (en) | 2014-12-29 | 2018-10-09 | Ethicon Llc | Methods and devices for inhibiting nerves when activating brown adipose tissue |
US10080884B2 (en) | 2014-12-29 | 2018-09-25 | Ethicon Llc | Methods and devices for activating brown adipose tissue using electrical energy |
US10391298B2 (en) | 2014-12-29 | 2019-08-27 | Ethicon Llc | Methods and devices for activating brown adipose tissue using electrical energy |
US10960201B2 (en) | 2014-12-29 | 2021-03-30 | Ethicon Llc | Methods and devices for inhibiting nerves when activating brown adipose tissue |
US10994123B2 (en) | 2014-12-29 | 2021-05-04 | Cilag Gmbh International | Methods and devices for activating brown adipose tissue using electrical energy |
US11679252B2 (en) | 2014-12-29 | 2023-06-20 | Cilag Gmbh International | Methods and devices for activating brown adipose tissue using electrical energy |
WO2016196209A1 (en) | 2015-05-29 | 2016-12-08 | Johnson & Johnson Consumer Inc. | Use of an organic citrus extract with high antimicrobial capacity and xylitol as a preservative system in liquids, emulsions, suspensions, creams and antacids |
US10342841B2 (en) | 2015-05-29 | 2019-07-09 | Johnson & Johnson Consumer Inc. | Use of an organic citrus extract with high antimicrobial capacity and xylitol as a preservative system in liquids, emulsions, suspensions, creams and antacids |
WO2016196205A1 (en) | 2015-05-29 | 2016-12-08 | Johnson & Johnson Consumer Inc. | Use of organic citrus extract with high antimicrobial capacity as a preservative system in liquids, emulsions, suspensions, creams and antacids |
Also Published As
Publication number | Publication date |
---|---|
CA2248854C (en) | 2004-03-30 |
EP0885008B1 (en) | 2009-12-30 |
CA2248854A1 (en) | 1998-04-09 |
EP0885008A1 (en) | 1998-12-23 |
EP0885008A4 (en) | 2000-12-20 |
DE69638106D1 (en) | 2010-02-11 |
ES2339908T3 (en) | 2010-05-26 |
ATE453385T1 (en) | 2010-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6224873B1 (en) | Regulation of appetite, body weight and athletic function with materials derived from citrus varieties | |
US6340482B1 (en) | Methods for inducing weight loss in a human with materials derived from Citrus varieties | |
US20060204599A1 (en) | Dietary supplement and method of using same | |
US5798101A (en) | Herbal appetite suppressant and weight loss composition | |
US7115285B2 (en) | Composition and method for appetite and craving suppression and mood enhancement | |
CA2248854C (en) | The regulation of appetite, body weight and athletic function with materials derived from citrus varieties | |
US20040077556A1 (en) | Compositions and methods for promoting weight loss, thermogenesis, appetite suppression, lean muscle mass, increasing metabolism and boosting energy levels, and use as a dietary supplement in mammals | |
AU2002364213B2 (en) | Compositions incorporating (-)-hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors | |
US5985282A (en) | Herbal appetite suppressant and weight loss composition | |
US20010043957A1 (en) | Lypolytic composition | |
WO2018112475A1 (en) | Energy compositions and methods | |
US6316499B1 (en) | Methods for increasing the muscle mass of a human with materials derived from citrus varieties | |
KR100455222B1 (en) | A diet ginseng products and the preparing method thereof | |
US6576272B1 (en) | Dietary supplement and method of using same | |
EP1093817B1 (en) | Composition containing compounds with adrenergic activity and vegetable extracts of crataegus and gingko biloba for the treatment of overweight and obesity | |
WO2003097078A1 (en) | Nutraceutical compositions comprising citrus alkaloids and method | |
WO2003097077A1 (en) | Novel dosage forms for materials derived from citrus varieties | |
US6426096B1 (en) | Anorexigenic composition | |
KR100441308B1 (en) | A diet ginseng drink and the preparing method thereof | |
US20180055849A1 (en) | Nutraceutical capsule and tablet formulations providing enhanced mental clarity, concentration and stamina while minimizing adrenaline and dopamine concentration perturbations associated with withdrawal | |
Greenway et al. | Herbal and alternative approaches to obesity | |
Hoffman | Energy drinks | |
US20090226550A1 (en) | Organic compositions and methods of use | |
Thurn | Ephedra (Ma Huang) | |
US20190142890A1 (en) | Dietary supplement derived from the senegalia plant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1996934144 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2248854 Country of ref document: CA Ref country code: CA Ref document number: 2248854 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09142197 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1996934144 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1998516473 Format of ref document f/p: F |